Venrock Healthcare Capital Partners

Managing Partners Nimish Shah and Bong Koh lead the investment team. Shah has led Venrock’s healthcare investments since the early 2000s and brings a long institutional memory of the firm’s life-sciences portfolio. Koh adds physician-level clinical perspective and prior venture experience. The partnership typically makes consensus-driven decisions, drawing on Venrock’s broader technology and operational network.

The firm descends directly from Venrock Associates, the venture capital firm founded in 1969 with backing from the Rockefeller family—specifically Laurance Rockefeller—and later expanded to manage outside limited-partner capital. Venrock Healthcare Capital Partners functions as the dedicated healthcare investment group within that heritage structure. It does not serve as a single-family office; it manages institutional capital alongside historical family-linked resources.

Venrock Healthcare Capital Partners invests across both private and public healthcare companies. The firm participates in private financing rounds from Seed through late-stage Growth and also takes positions in publicly traded biotech, diagnostics, and digital health companies, often via crossover rounds or open-market purchases when scientific or regulatory catalysts align with the partnership’s domain expertise.

Stage coverage spans Seed, Start-up, Expansion/Late Stage, and Growth. The firm has historically been comfortable leading or co-leading both early-stage company formations and later-stage pre-IPO rounds in biotech and medical devices. Its public-market activity adds a crossover capability that extends the holding period beyond what a pure venture fund typically pursues.

The firm focuses on therapeutics—including genetic medicines, oncology, and radiopharmaceuticals—along with medical devices, diagnostics, and digital health. It has publicly discussed conviction in AI-enabled drug discovery, translational biology platforms, and care-delivery models that reduce clinical friction. Historically, it has avoided pure health-insurance or hospital-operating company investments in favor of innovation-driven asset classes.

Venrock Healthcare Capital Partners operates within Venrock’s overall fund structure rather than as a separately branded fund management company. The healthcare strategy receives discrete partnership-level leadership and investment committee authority. The firm has not disclosed a standalone healthcare-only fund close, but Shah and Koh’s team drives the sector allocation from within the broader Venrock partnership.

Venrock Healthcare Capital Partners regularly syndicates with top-tier crossover and life-science specialists, including blue-chip biotechnology funds and public-market healthcare investors. The partnership values collaborative financing rounds that aggregate domain-specific due diligence, and Venrock’s technology-side partners occasionally join syndicates when a portfolio company sits at the intersection of biology and software.